Erratum to: Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer (Targeted Oncology (2014) 9, (9-24) DOI: 10.1007/s11523-013-0304-7);Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer

Targeted Oncology

Volumn 9, Issue 1, 2014, Pages 9-24

  León, Luís ^a,h   García Figueras, Roberto ^a   Suárez, Cristina ^b   Arjonilla, Antonia ^c   Puente, Javier ^d   Vargas, Blanca ^e   Méndez Vidal, Maria José ^f   Sebastiá, Carmen ^g  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL UNIVERSITARIO REY JUAN CARLOS   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

^h University Hospital of Santiago de Compostela   (Spain)

Author keywords

Antiangiogenic therapy; Choi; Functional imaging; MASS; Metastatic renal cell carcinoma; RECIST

Indexed keywords

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; DRUG TARGETING; HUMAN; KIDNEY METASTASIS; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TISSUE PERFUSION; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR VOLUME; CARCINOMA, RENAL CELL; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; KIDNEY NEOPLASMS; METASTASIS; PATHOLOGY; PRACTICE GUIDELINE; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENT; PHARMACOLOGICAL BIOMARKER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DIAGNOSTIC IMAGING; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; TREATMENT OUTCOME;

EID: 84899409035     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-014-0317-x     Document Type: Erratum

References (81)

1. Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353:2477-2490. doi:10.1056/NEJMra043172 (Pubitemid 41770167)
2. Brugarolas J (2007) Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med 356:185-187. doi:10.1056/NEJMe068263
3. Li L, Kaelin WG Jr (2011) New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am 25:667-686. doi:10.1016/j.hoc.2011.04.004
4. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM et al (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85-90. doi:10.1038/ng0594-85 (Pubitemid 24232386)
5. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA (1996) Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 93:10595-10599 (Pubitemid 26333032)
6. Koul H, Huh JS, Rove KO, Crompton L, Koul S, Meacham RB, Kim FJ (2011) Molecular aspects of renal cell carcinoma: a review. Am J Cancer Res 1:240-254
7. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275. doi:10.1038/20459 (Pubitemid 29246458)
8. Na X, Wu G, Ryan CK, Schoen SR, di'Santagnese PA, Messing EM (2003) Overproduction of vascular endothelial growth factor related to von Hippel - Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol 170:588-592. doi:10.1097/01.ju. 0000074870.54671.98 (Pubitemid 36870265)
9. Bedke J, Gouttefangeas C, Singh-Jasuja H, Stevanovic S, Behnes CL, Stenzl A (2013) Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World J Urol. doi:10.1007/s00345-013-1033-3
10. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103-2111. doi:10.1016/S0140-6736(07)61904-7 (Pubitemid 350296300)
11. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422-5428. doi:10.1200/JCO.2008.16.9847
12. Albiges L, Salem M, Rini B, Escudier B (2011) Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. Hematol Oncol Clin North Am 25:813-833. doi:10.1016/j.hoc.2011.04.006
13. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281. doi:10.1056/NEJMoa066838 (Pubitemid 46849157)
14. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456. doi:10.1016/S0140-6736(08)61039-9
15. Nathan PD, Vinayan A, Stott D, Juttla J, Goh V (2010) CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 9:15-19
16. Shinagare AB, Krajewski KM, Jagannathan JP, Ramaiya NH (2012) Genitourinary imaging: part 2, role of imaging in medical management of advanced renal cell carcinoma. AJR Am J Roentgenol 199: W554-W564. doi:10.2214/AJR.12. 9233
17. Flaherty KT, Rosen MA, Heitjan DF, Gallagher ML, Schwartz B, Schnall MD, O'Dwyer PJ (2008) Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 7:496-501 (Pubitemid 351847022)
18. Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ, Stadler WM (2008) Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 26:4572-4578. doi:10.1200/JCO.2007.15.5655
19. Lamuraglia M, Escudier B, Chami L, Schwartz B, Leclere J, Roche A, Lassau N (2006) To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 42:2472-2479. doi:10.1016/j.ejca.2006.04.023 (Pubitemid 44442955)
20. Fournier LS, Oudard S, Thiam R, Trinquart L, Banu E, Medioni J, Balvay D, Chatellier G, Frija G, Cuenod CA (2010) Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology 256:511-518. doi:10.1148/radiol.10091362
21. Han KS, Jung DC, Choi HJ, Jeong MS, Cho KS, Joung JY, Seo HK, Lee KH, Chung J (2010) Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. Cancer 116:2332-2342. doi:10.1002/cncr.25019
22. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Boven E (2010) Targeted therapies in renal cell cancer: recent developments in imaging. Target Oncol 5:95-112. doi:10.1007/s11523-010-0146-5
23. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214 (Pubitemid 11167383)
24. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247. doi:10.1016/j.ejca.2008.10.026
25. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P (2000) Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 356:373-378 (Pubitemid 30487493)
26. Fleming TR, DeMets DL (1996) Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125:605-613 (Pubitemid 126450094)
27. Flaherty KT (2007) Sorafenib in renal cell carcinoma. Clin Cancer Res 13:747s-752s. doi:10.1158/1078-0432.CCR-06-2063
28. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8:975-984. doi:10.1016/S1470-2045(07)70285-1 (Pubitemid 47629888)
29. Rodriguez Faba O, Breda A, Rosales A, Palou J, Algaba F, Maroto Rey P, Villavicencio H (2010) Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma. Eur Urol 58:307-310. doi:10.1016/j.eururo.2010.03.005
30. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E (2010) Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 102:803-809. doi:10.1038/sj.bjc.6605567
31. Smith AD, Lieber ML, Shah SN (2010) Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contraste-nhanced CT. AJR Am J Roentgenol 194:157-165. doi:10.2214/AJR.09.2941
32. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM (2010) Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 194:1470-1478. doi:10.2214/AJR.09.3456
33. Krajewski KM, Guo M, Van den Abbeele AD, Yap J, Ramaiya N, Jagannathan J, Heng DY, Atkins MB, McDermott DF, Schutz FA, Pedrosa I, Choueiri TK (2011) Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol 59:856-862. doi:10.1016/j.eururo.2011. 01.038
34. Jain Y, Liew S, Taylor MB, Bonington SC (2011) Is dual-phase abdominal CT necessary for the optimal detection ofmetastases from renal cell carcinoma? Clin Radiol 66:1055-1059. doi:10.1016/j.crad.2011.06.002
35. Patel U, Sokhi H (2012) Imaging in the follow-up of renal cell carcinoma. AJR Am J Roentgenol 198:1266-1276. doi:10.2214/AJR.11.8381
36. Raptopoulos VD, Blake SP, Weisinger K, Atkins MB, Keogan MT, Kruskal JB (2001) Multiphase contrast-enhanced helical CT of liver metastases from renal cell carcinoma. Eur Radiol 11:2504-2509. doi:10.1007/s003300100853 (Pubitemid 33114907)
37. O'Connor JP, Jayson GC (2012) Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors? Clin Cancer Res 18:6588-6598. doi:10.1158/1078-0432.CCR-12-1501
38. Thiam R, Fournier LS, Trinquart L, Medioni J, Chatellier G, Balvay D, Escudier B, Dromain C, Cuenod CA, Oudard S (2010) Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol 21:936-941. doi:10.1093/annonc/mdp466
39. Oudard S, Thiam R, Fournier LS, Medioni J, Lamuraglia M, Scotte F, Fabre E, Kim D, Kpamegan E, Panneerselvam A, Cuenod CA (2012) Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study. Eur J Cancer 48:1512-1518. doi:10.1016/j.ejca.2012.01.027
40. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530-2540 (Pubitemid 29368255)
41. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794-5799. doi:10.1200/JCO.2008.21.4809
42. Manola J, Royston P, Elson P, McCormack JB, Mazumdar M, Negrier S, Escudier B, Eisen T, Dutcher J, Atkins M, Heng DY, Choueiri TK, Motzer R, Bukowski R (2011) Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res 17: 5443-5450. doi:10.1158/1078-0432.CCR-11-0553
43. Armstrong AJ, George DJ, Halabi S (2012) Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol 30:3402-3407. doi:10.1200/JCO.2011.40.9631
44. Ollivier L, Leclère J, Thiesse P, Di Stefano D, Vincent C (2007) Évaluation de la réponse thérapeutique en cancérologie: le rôle de l'imagerie morphologique. Bull Cancer 94:171-177 (Pubitemid 46456111)
45. Schwartz LH, Mazumdar M, Wang L, Smith A, Marion S, Panicek DM, Motzer RJ (2003) Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials. Cancer 98:1611-1619. doi:10.1002/cncr. 11712 (Pubitemid 37238616)
46. Nishino M, Jagannathan JP, Krajewski KM, O'Regan K, Hatabu H, Shapiro G, Ramaiya NH (2012) Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol 198:737-745. doi:10.2214/AJR.11.7483
47. Castel P, Tassy L, Lurkin A, Blay JY, Meeus P, Mignotte H, Faure C, Ranchere-Vince D, Bachelot T, Guastalla JP, Sunyach MP, Guerin N, Treilleux I, Marec-Berard P, Thiesse P, Ray-Coquard I (2012) Multidisciplinarity and medical decision, impact for patients with cancer: sociological assessment of two tumour committees' organization. Bull Cancer 99:E34-E42. doi:10.1684/bdc.2012.1559
48. Lamb BW, Sevdalis N, Taylor C, Vincent C, Green JS (2012) Multidisciplinary team working across different tumour types: analysis of a national survey. Ann Oncol 23:1293-1300. doi:10.1093/annonc/mdr453
49. Figueiras RG, Padhani AR, Goh VJ, Vilanova JC, Gonzalez SB, Martin CV, Caamano AG, Naveira AB, Choyke PL (2011) Novel oncologic drugs: what they do and how they affect images. Radiographics 31:2059-2091. doi:10.1148/rg.317115108
50. Negrier S, Ollivier L, Di Stefano-Louineau D, Escudier B, Savary J, Lasset C, Thiesse P (2000) Reliability of the response rate in oncology: analysis of the causes for variation. Bull Cancer 87:927-934 (Pubitemid 32094654)
51. Suzuki C, Jacobsson H, Hatschek T, Torkzad MR, Boden K, Eriksson-Alm Y, Berg E, Fujii H, Kubo A, Blomqvist L (2008) Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 28:329-344. doi:10.1148/rg.282075068
52. Katabathina VS, Lassau N, Pedrosa I, Ng CS, Prasad SR (2012) Evaluation of treatment response in patients with metastatic renal cell carcinoma: role of state-of-the-art cross-sectional imaging. Curr Urol Rep 13:70-81. doi:10.1007/s11934-011-0233-x
53. European ALARA Network. http://www.eu-alara.net/. Accessed 10 Oct 2013
54. Faria SC, Ng CS, Hess KR, Phongkitkarun S, Szejnfeld J, Daliani D, Charnsangavej C (2007) CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma. AJR Am J Roentgenol 189:378-385. doi:10.2214/AJR.07.2164 (Pubitemid 47195923)
55. Hugonnet F, Fournier L, Medioni J, Smadja C, Hindie E, Huchet V, Itti E, Cuenod CA, Chatellier G, Oudard S, Faraggi M (2011) Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18 F-fluoromisonidazole PET/CT study. J Nucl Med 52: 1048-1055. doi:10.2967/jnumed.110.084517
56. Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, Nathan P, Wilson P, Shamash J, Sharpe K, Lim L, Dickson J, Ell P, Reynolds A, Powles T (2011) Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Clin Cancer Res 17:6021-6028. doi:10.1158/1078-0432.CCR-10-3309
57. Maksimovic O, Schraml C, Hartmann JT, Bitzer M, Claussen CD, Pintoffl J, Horger M (2010) Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment. AJR Am J Roentgenol 194:5-14. doi:10.2214/AJR.09.2744
58. Williams R, Hudson JM, Lloyd BA, Sureshkumar AR, Lueck G, Milot L, Atri M, Bjarnason GA, Burns PN (2011) Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy. Radiology 260:581-590. doi:10.1148/radiol.11101893
59. Aboagye EO, Gilbert FJ, Fleming IN, Beer AJ, Cunningham VJ, Marsden PK, Visvikis D, Gee AD, Groves AM, Kenny LM, Cook GJ, Kinahan PE, Myers M, Clarke L (2012) Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials. Eur Radiol 22:1465-1478. doi:10.1007/s00330-011-2311-3
60. Leach MO, Morgan B, Tofts PS, Buckley DL, Huang W, Horsfield MA, Chenevert TL, Collins DJ, Jackson A, Lomas D, Whitcher B, Clarke L, Plummer R, Judson I, Jones R, Alonzi R, Brunner T, Koh DM, Murphy P, Waterton JC, Parker G, Graves MJ, Scheenen TW, Redpath TW, Orton M, Karczmar G, Huisman H, Barentsz J, Padhani A (2012) Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. Eur Radiol 22:1451-1464. doi:10.1007/s00330-012-2446-x
61. Leen E, Averkiou M, Arditi M, Burns P, Bokor D, Gauthier T, Kono Y, Lucidarme O (2012) Dynamic contrast enhanced ultrasound assessment of the vascular effects of novel therapeutics in early stage trials. Eur Radiol 22:1442-1450. doi:10.1007/s00330-011-2373-2
62. Miles KA, Lee TY, Goh V, Klotz E, Cuenod C, Bisdas S, Groves AM, Hayball MP, Alonzi R, Brunner T (2012) Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography. Eur Radiol 22: 1430-1441. doi:10.1007/s00330-012-2379-4
63. Goh V, Ng QS, Miles K (2012) Computed tomography perfusion imaging for therapeutic assessment: has it come of age as a biomarker in oncology? Invest Radiol 47:2-4. doi:10.1097/RLI.0b013e318229ff3e
64. Garcia-Figueiras R, Goh VJ, Padhani AR, Baleato-Gonzalez S, Garrido M, Leon L, Gomez-Caamano A (2013) CT perfusion in oncologic imaging: a useful tool? AJR Am J Roentgenol 200:8-19. doi:10.2214/AJR.11.8476
65. Chen Y, Zhang J, Dai J, Feng X, Lu H, Zhou C (2010) Angiogenesis of renal cell carcinoma: perfusion CT findings. Abdom Imaging 35: 622-628. doi:10.1007/s00261-009-9565-0
66. Zhang YL, Ren J, Yu BL, Qu K, Wang K, Qiang YQ, Li CX, Sun XW, Li Z (2012) Utility of CT perfusion imaging for grading of clear cell renal cell carcinoma. Hereditary Genet 1:1-5. doi:10.4172/2161-1041.1000105
67. Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D, Hammoud DA, Rustin GJ, Taouli B, Choyke PL (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102-125
68. Padhani AR, Koh DM (2011) Diffusion MR imaging for monitoring of treatment response. Magn Reson Imaging Clin N Am 19:181-209. doi:10.1016/j.mric.2010.10.004
69. Desar IM, ter Voert EG, Hambrock T, van Asten JJ, van Spronsen DJ, Mulders PF, Heerschap A, van der Graaf WT, van Laarhoven HW, van Herpen CM (2011) Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study. Cancer Imaging 11:259-265. doi:10.1102/1470-7330.2011.0032
70. Gary R, Mac Vicar, Frank Miller, Rahul Rustogi, Zong-Ming Chen, Brenda K. Martone, Kuzel. T (2013) Correlation of pathologic findings after brief neoadjuvant sorafenib with results of dynamiccontrast enhanced (DCE) and diffusion-weighted magnetic resonance imaging (DW-MRI) in patients with locally advanced or metastatic clear cell renal cell carcinoma (RCC). J Clin Oncol 31 (Suppl 6): abstract 466
71. Leary A, Pickering LM, Larkin JMG, Leach MO, Gore ME, Sohaib A, Collins DJ, Koh D (2011) Quantitative diffusion-weighted (DW) MR imaging of microcapillary perfusion and tissue diffusivity as biomarkers of response of renal cell carcinoma (RCC) to treatment with sunitinib. ASCO Meeting Abstracts 29:TPS154
72. Platzek I, Zastrow S, Deppe PE, Grimm MO, Wirth M, Laniado M, Stroszczynski C (2010) Whole-body MRI in follow-up of patients with renal cell carcinoma. Acta Radiol 51:581-589. doi:10.3109/02841851003724846
73. Lyrdal D, Boijsen M, Suurkula M, Lundstam S, Stierner U (2009) Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. Nucl Med Commun 30:519-524
74. Vercellino L, Bousquet G, Baillet G, Barre E, Mathieu O, Just PA, Desgrandchamps F, Misset JL, Hindie E, Moretti JL (2009) 18 FFDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm 24:137-144. doi:10.1089/cbr.2008. 0527
75. Liu G, Jeraj R, Perlman S, Vanderhoek M, Kolesar J, Eickhoff J, Alberti D, Wilding G (2008) Pharmacodynamic study of FLT-PET imaging in patients treated with sunitinib. ASCO Meet Abstr 26:3515
76. Beer AJ, Kessler H, Wester HJ, Schwaiger M(2011) PET Imaging of Integrin alphaVbeta3 Expression. Theranostics 1:48-57
77. Backer MV, Backer JM (2012) Imaging key biomarkers of tumor angiogenesis. Theranostics 2:502-515. doi:10.7150/thno.3623
78. Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester HJ, Peschel C, Lordick F, Schwaiger M (2008) Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18 F-galacto-RGD and 18 F-FDG. J Nucl Med 49:22-29. doi:10.2967/jnumed.107.045864
79. NagengastWB, de Korte MA, Oude Munnink TH, Timmer-Bosscha H, den Dunnen WF, Hollema H, de Jong JR, Jensen MR, Quadt C, Garcia-Echeverria C, van Dongen GA, Lub-de Hooge MN, Schroder CP, de Vries EG (2010) 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med 51:761-767. doi:10.2967/jnumed.109.071043
80. Wang JQ, Miller KD, Sledge GW, Zheng QH (2005) Synthesis of [18 F]SU11248, a new potential PET tracer for imaging cancer tyrosine kinase. Bioorg Med Chem Lett 15:4380-4384. doi:10.1016/j.bmcl.2005.06.038 (Pubitemid 41199807)
81. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216